Neonatal Encephalopathy clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
High-dose Erythropoietin or placebo for birth asphyxia and neonatal encephalopathy
“Study looking at High-dose Erythropoietin with standard care or placebo with standard of care has better outcomes for infants with HIE”
open to all eligible people
Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth. This results in death or neurologic disabilities including cerebral palsy and cognitive impairment in up to half of affected infants. This clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual therapy) will improve outcomes for infants suffering from HIE.
San Francisco, California and other locations